|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment
1 Clinical Development, Diabetes, and
2 Clinical Statistics, Novo Nordisk A/S, Bagsvaerd, Denmark
3 Division of Clinical Pharmacology, University of Miami School of Medicine, Miami, Florida
OBJECTIVE—To assess the efficacy and safety of glucagon-like peptide-1 (GLP-1) on the plasma glucose level when given as a continuous infusion for either 16 or 24 h per day to type 2 diabetic patients who were poorly controlled on sulfonylurea treatment.
RESEARCH DESIGN AND METHODS—This single-center, randomized, parallel, double-blind, placebo-controlled trial was conducted in 40 hospitalized patients who were randomized to receive infusions of either placebo or GLP-1 4 or 8 ng · kg–1 · min–1 for either 16 or 24 h per day for 7 days. At predetermined intervals, 24-h profiles of glucose, glucagon, and insulin were measured. Adverse events and clinical chemistry and hematology were recorded.
RESULTS—For all active treatment groups, the change in average glucose (area under the curve [AUC] for day 7 minus AUC for day 0 divided by 24 h) was statistically significantly different from placebo (P 
0.001). The GLP-1 8 ng · kg–1 · min–1 dose given for 24 h was more efficacious than any of the other doses (P 0.05). Nocturnal and fasting plasma glucose levels at day 7 were greater in the 16-h groups compared with the 24-h groups (P 0.05). Insulin AUC did not show any treatment effect for any of the treatment groups when change was assessed from day 0 to day 7. However, for the 16-h groups, the pattern of the insulin profiles changed; the insulin profiles were considerably higher during the initial 3–4 h after restart of the GLP-1 infusion on day 7, although there was a tendency for insulin levels to decrease during the afternoon and evening. Glucagon AUC decreased significantly for all active treatment groups compared with placebo. GLP-1 was generally well tolerated.
CONCLUSIONS—This study demonstrated that GLP-1 should be given continuously to obtain the most optimal glycemic control. Because of the short plasma half-life of native GLP-1, long-acting derivatives should be developed to make GLP-1 treatment clinically relevant.
Abbreviations: AE, adverse events • ANOVA, analysis of variance • AUC, area under the curve • BG, blood glucose • DPP-IV, dipeptidyl peptidase IV • FPG, fasting plasma glucose • GLP-1, glucagon-like peptide-1 • SU, sulfonylurea
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  K. M. Picha, M. R. Cunningham, D. J. Drucker, A. Mathur, T. Ort, M. Scully, A. Soderman, T. Spinka-Doms, V. Stojanovic-Susulic, B. A. Thomas, et al. Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor-Dependent Control of Glucose Homeostasis Diabetes, July 1, 2008; 57(7): 1926 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Lamont and D. J. Drucker Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat Fed Mice Diabetes, January 1, 2008; 57(1): 190 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kim, L. MacConell, D. Zhuang, P. A. Kothare, M. Trautmann, M. Fineman, and K. Taylor Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes Diabetes Care, June 1, 2007; 30(6): 1487 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Haines Emerging Treatments for Patients With Type 2 Diabetes The Diabetes Educator, May 1, 2007; 33(Supplement_5): 105S - 110S. [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Knudsen, D. Kiel, M. Teng, C. Behrens, D. Bhumralkar, J. T. Kodra, J. J. Holst, C. B. Jeppesen, M. D. Johnson, J. C. de Jong, et al. From the Cover: Small-molecule agonists for the glucagon-like peptide 1 receptor PNAS, January 16, 2007; 104(3): 937 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Raun, P. von Voss, C. F. Gotfredsen, V. Golozoubova, B. Rolin, and L. B. Knudsen Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not Diabetes, January 1, 2007; 56(1): 8 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Damholt, G. Golor, W. Wierich, P. Pedersen, M. Ekblom, and M. Zdravkovic An Open-Label, Parallel Group Study Investigating the Effects of Age and Gender on the Pharmacokinetics of the Once-Daily Glucagon-Like Peptide-1 Analogue Liraglutide. J. Clin. Pharmacol., June 1, 2006; 46(6): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V Joy, P. T Rodgers, and A. C Scates Incretin Mimetics as Emerging Treatments for Type 2 Diabetes Ann. Pharmacother., January 1, 2005; 39(1): 110 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Baggio, J.-G. Kim, and D. J. Drucker Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R-Dependent Glucose Homeostasis In Vivo Diabetes, December 1, 2004; 53(suppl_3): S205 - S214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Madsbad, O. Schmitz, J. Ranstam, G. Jakobsen, and D. R. Matthews Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial Diabetes Care, June 1, 2004; 27(6): 1335 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Degn, C. B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B. R. Landau, and O. Schmitz One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and {alpha}- and {beta}-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes Diabetes, May 1, 2004; 53(5): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Meneilly, N. Greig, H. Tildesley, J. F. Habener, J. M. Egan, and D. Elahi Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2835 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Meier, B. Gallwitz, S. Salmen, O. Goetze, J. J. Holst, W. E. Schmidt, and M. A. Nauck Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2719 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Kjems, J. J. Holst, A. Volund, and S. Madsbad The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on {beta}-Cell Sensitivity in Type 2 and Nondiabetic Subjects Diabetes, February 1, 2003; 52(2): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Perry, N. J. Haughey, M. P. Mattson, J. M. Egan, and N. H. Greig Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4 J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 881 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Elbrond, G. Jakobsen, S. Larsen, H. Agerso, L. B. Jensen, P. Rolan, J. Sturis, V. Hatorp, and M. Zdravkovic Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects Diabetes Care, August 1, 2002; 25(8): 1398 - 1404. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |